Nolpaza (Pantoprazole)

Pantoprazole, the active ingredient in Nolpaza, is a proton pump inhibitor presented as an intravenous solution for intravenous use. It reduces gastric acid secretion and is employed to manage gastro‑esophageal reflux disease, erosive esophagitis, Zollinger‑Ellison syndrome, and peptic ulcer disease in adult patients. It is indicated for patients requiring rapid acid control in acute care settings.

GNH USA supplies Nolpaza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global healthcare institutions.

Pantoprazole is a proton pump inhibitor used to treat conditions related to excess gastric acid production.

- Gastro‑esophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Erosive esophagitis: facilitates mucosal healing and decreases further erosion. - Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid associated with gastrin‑producing tumors. - Peptic ulcer disease: promotes ulcer healing by maintaining a less acidic gastric environment.

Pantoprazole may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head. - Diarrhea: loose stools occurring during treatment. - Nausea: feeling of sickness or urge to vomit. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with airway compromise. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: serious skin and mucous membrane disorders. - Clostridioides difficile‑associated colitis: severe intestinal infection.

Before initiating intravenous pantoprazole, clinicians should consider several safety precautions to minimize risks. - Assess renal function: dose adjustment may be needed in severe impairment. - Monitor serum magnesium: prolonged therapy can cause hypomagnesemia. - Evaluate hepatic status: use with caution in patients with liver disease. - Review concomitant medications: potential for reduced efficacy of drugs requiring gastric acidity. - Consider risk of Clostridioides difficile infection: monitor for persistent diarrhea. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Pantoprazole can alter the pharmacokinetics of several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Ketoconazole, itraconazole and other azole antifungals: reduced absorption due to increased gastric pH. - Atazanavir and other protease inhibitors: markedly decreased plasma concentrations. - Rilpivirine: loss of antiviral effect from decreased absorption. - Methotrexate: increased serum levels and risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of anticoagulant effect, monitor INR. - Digoxin: slight increase in serum concentration, observe for toxicity. - Clopidogrel: reduced activation may diminish antiplatelet activity. - Phenytoin: potential increase in free drug levels.